UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs

RA’ANANA, Israel, and NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- UroGen (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointments of Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs. Mr. Ottinger and Mr. Bova will report to Ron Bentsur, Chief Executive Officer of UroGen Pharma, and will be based in UroGen Pharma’s New York office.

“Jeff and Jim bring proven track records of success in their respective careers, and we are thrilled to welcome them to our senior leadership team,” said Mr. Bentsur. “We believe Jeff and Jim’s expertise will fortify our commercial and regulatory capabilities as we further advance our product candidates and execute on our goal of becoming a leading uro-oncology company.”

Jeffrey Bova, M.B.A., as Vice President of Commercial

Jeffrey Bova is a pharmaceutical commercial leader with extensive leadership experience across key commercial functional areas, including national sales, marketing and managed care. Mr. Bova joins UroGen Pharma after 20 years at Bayer Healthcare, where he held multiple senior-level sales leadership positions of increasing responsibility. Most recently at Bayer, Mr. Bova served as Vice President of Oncology Sales where he led over 200 field-facing sales representatives marketing well-known brands including Xofigo^®, Stivarga^® and Nexavar^®. Mr. Bova also previously served as Bayer’s Vice President of Marketing for Bayer’s prostate cancer franchise where he designed, developed and led Bayer’s highly successful launch of Xofigo^®. Mr. Bova received his M.B.A. from Xavier University and his B.S. in finance and marketing from the University of Cincinnati.

James Ottinger, R.Ph., as Vice President of Regulatory Affairs

James Ottinger is a seasoned regulatory executive with over 30 years of strategic regulatory leadership experience and has successfully supported the development, approval, and marketing of multiple new drugs throughout his career. Prior to joining UroGen Pharma, Mr. Ottinger served as Senior Vice President of Global Regulatory Affairs at Teva Pharmaceutical Industries, Inc., where he was responsible for global regulatory oversight of Teva’s portfolio of branded, generic, and over-the-counter products. Previously, Mr. Ottinger was Vice President of Worldwide Regulatory Affairs of Cephalon, Inc. (acquired by Teva). Earlier in his career, Mr. Ottinger held a variety of senior regulatory leadership positions with Premier Research Group Limited, and regulatory positions of increasing responsibility at Wyeth Research (acquired by Pfizer, Inc.). Mr. Ottinger received his B.S. in Pharmacy from the Temple University School of Pharmacy and is a registered pharmacist in the State of Pennsylvania.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel™, a proprietary sustained release, hydrogel-based formulation for potentially improving therapeutic profiles of existing drugs. UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma’s lead product candidates, MitoGel™ and VesiGel™, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer. UroGen Pharma is headquartered in Ra’anana, Israel and maintains a corporate office in New York City.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the clinical development and commercial prospects of the product candidates in UroGen Pharma’s pipeline, the scope and development of UroGen Pharma’s product candidate pipeline, and the ability of UroGen Pharma to become a leader in the field of uro-oncology, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential complications thereof; the ability to obtain and maintain regulatory approval; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen Pharma’s product candidates; and the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of the final prospectus for UroGen Pharma’s initial public offering of securities in the United States filed with the SEC on May 5, 2017 and other filings that UroGen Pharma makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen Pharma’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen Pharma as of the date of this release.

CONTACTS:

Burns McClellan, Inc.
Steve Klass
sklass@burnsmc.com
212-213-0006